Drug intelligence / Profile preview

ALG-901

Development stage: Preclinical
Lead developer: AliveGen

Overview

ALG-901 is an investigational biologic candidate currently in the discovery stage of development by AliveGen. It is being developed for the treatment of metabolic disorders. While specific details regarding its molecular target and mechanism of action have not been publicly disclosed, AliveGen's research platform generally focuses on the modulation of the TGF-beta superfamily and other signaling pathways involved in muscle growth, wasting, and cardiometabolic health. The program represents an early-stage expansion of the company's pipeline, which includes other candidates like ALG-801 that target myostatin and activin pathways.

Targets

GDF11 (Growth differentiation factor 11)

Beyond the preview

Go deeper on ALG-901.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALG-901.

Explore the full profile